RxDoctor Payments Data

Kelly Getz

Adult Health · Abingdon, MDNPI 1700481769

Payments from drug & device makers

$1,945in general payments, 2019–2025

Across 101 payments — averaging $19.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$902
  • Collegium Pharmaceutical, Inc.$188
  • Orexo US, Inc.$98
  • GRT US Holding, Inc.$91
  • Pacira Therapeutics, Inc.$89
  • Baudax Bio Inc.$64
  • plus $513 from 16 others

What the payments were for

  • Food & beverage$1,945100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,945 in reported general payments places this provider in the 80th percentile of 542 adult health providers in Maryland.

See all adult health providers in Maryland

Medicare billing

Part B allowed, 2024
$47,710
Medicare patients
57
Services billed
485

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide45$50,829
OxycontinOxycodone Hcl42$26,217
VraylarCariprazine Hcl14$19,444
Oxycodone Hcl341$9,533
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,768
LinzessLinaclotide12$7,620
SymproicNaldemedine Tosylate11$7,427
Xtampza ErOxycodone Myristate13$6,882
Butalb-Acetaminoph-Caff-CodeinButalbit/Acetamin/Caff/Codeine12$3,233
Lubiprostone12$2,525
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen67$2,292
Tramadol Hcl ErTramadol Hcl24$1,994
Gabapentin158$1,609
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen47$1,523
Naloxone Hcl22$1,523

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$51$50,82945 claims
AbbVieVraylar, Linzess$902$27,06426 claims
Collegium Pharmaceutical, Inc.Xtampza Er$188$6,88213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 542 adult health providers in Maryland.

Other adult health in Abingdon

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →